Business Wire

CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport

Jaa

Please replace the release with the following corrected version due to multiple revisions to the headline, subhead and body of the release.

The corrected release reads:

SMITHS DETECTION WINS BIGGEST EVER SINGLE ORDER FOR NEXT-GENERATION HOLD BAGGAGE SCANNER FOR FRANKFURT AIRPORT

Advanced HI-SCAN 10080 XCT hold baggage scanners offer flexible, sophisticated detection capabilities

Smiths Detection has won its largest single order ever for its advanced HI-SCAN 10080 XCT hold baggage scanners, with an associated eight-year service agreement. The contract covers 35 of our HI-SCAN 10080 XCT next-generation scanners to support the upgrade to the ECAC Standard 3 explosives detection systems. The solution will deliver increased security and operational efficiency, and can easily be upgraded to meet future requirements to identify evolving threats, such as homemade explosives.

Frankfurt is Europe’s second busiest airport in terms of cargo and fourth in terms of passenger numbers, with over 60 million in 2016, making a high-speed, high volume hold baggage system critical to screening efficiency.

The HI-SCAN 10080 XCT scanner combines high-resolution X-ray technology, medical-quality computed tomography (CT) and advanced detection algorithms to deliver exceptional levels of security. It supports a high throughput of up to 1,800 bags per hour, can accommodate items measuring up to 1,000 x 800 mm, and operates with a low false alarm rate to deliver a highly efficient screening process.

Delivery will take place on a rolling basis between 2018 and 2021 with the order also including an eight year service agreement. The scanners will be used in Terminals 1 and 2 and will be operated by the German Federal Police.

“This contract represents our largest single order to date for ECAC Standard 3-compliant hold baggage scanners,” commented Tony Tielen, VP of EMEA for Smiths Detection. “Frankfurt was one of the very first airports we supplied with security equipment over fifty years ago, and we’re delighted to have the opportunity to continue protecting Germany’s busiest airport.”

Ends

Notes to editors

HI-SCAN 10080 XCT key features:

  • EU/ECAC EDS Standard 3 approved
  • Laboratory certified for high-speed checked baggage screening by the United States Transportation Security Administration (TSA)
  • Belt speed of 0.5m/sec (98.5ft/min)
  • High throughput of up to 1800 bags per hour
  • Large tunnel capable of screening objects 100 x 80 cm (39.4 x 31.5in)

A dual-energy X-ray line scanner with full 3D volumetric Computed Tomography (CT) imaging and reconstruction, the HI-SCAN 10080 XCT is the next generation high-speed checked baggage explosives detection system (EDS).

With a belt speed of 0.5m/sec (98.5ft/min) and a large 1070 x 810mm (42.1 x 31.9in) rectangular tunnel, the HI-SCAN 10080 XCT provides the most economical solution for airport checked baggage screening requirements. This combination of belt speed and tunnel size will provide baggage handling systems the capability to process a throughput of up to 1800 bags/hour with object sizes of up to 1000 x 800 mm (39.4 x 31.5in).

The HI-SCAN 10080 XCT is designed to integrate easily into newly implemented Hold Baggage System (HBS) configurations or as a replacement for current baggage handling systems.

Further details on the Smiths Detection HI-SCAN 10080 XCT can be found here: http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=157:hi-scan-10080-xct&Itemid=101&lang=en#.WKwoEoXXLmg

About Smiths Detection

Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for military, air transportation, homeland security and emergency response markets. Our experience and history across more than 50 years at the frontline, enables us to provide unrivalled levels of expertise to detect and identify constantly changing chemical, radiological, nuclear and explosive threats, as well as weapons, dangerous goods, contraband and narcotics.

Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com; or follow us on LinkedIn at www.linkedin.com/company/smiths-detection; YouTube at www.youtube.com/user/smithsdetectiongroup; or Twitter at twitter.com/smithsdetection.

Contact information

Smiths Detection
Karen Kulinski
Global Aviation Marketing Director
+49 (0)611 9412 422
karen.kulinski@smithsdetection.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23Tiedote

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo

Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13Tiedote

Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at marian.salzman@pmi.com. “People who smoke deserve in

IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30Tiedote

IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec

Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23Tiedote

Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and

Phlexglobal to Improve eTMF Document Transfers with Adoption of New Exchange Mechanism Standard21.6.2018 19:16Tiedote

Phlexglobal, a specialist provider of technology-enabled Trial Master File (TMF & eTMF) management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. This marks a major advancement in efficient document interchange and will firmly solidify Phlexglobal’s position as a driving force in eTMF management for clinical trials. Prior to the creation of the TMF Reference Model, there was no universal methodology for the organization of trial data in an eTMF. In 2009 Phlexglobal joined other industry TMF experts to create the TMF Reference Model which has primarily focused on organizing the artifacts of a clinical trial. While the TMF-RM has aided in the organization of artifact, the transfer of TMF to trial sponsors or contract research organizations has often required a significant amount of mapping and manipulation. Phlexglobal has extensive experience migrating millions of TMF

IDEMIA: Enter the World of Augmented Identity at our Pop-up Innovation Center in London (25th-27th June 2018)21.6.2018 17:36Tiedote

IDEMIA, the global leader in Augmented Identity, is announcing the opening of its Pop-up Innovation Center, at the heart of London, in Westminster (“Queen Elizabeth II Center”). It will take place from 25th to 27th of June, 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005800/en/ IDEMIA’s ambition is to enable a secure and trusted environment for citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel, vote or access public or private spaces), in the real as well as digital worlds. Opening its unique Pop-up Innovation Center, IDEMIA invites you to experience its innovative solutions through dedicated demonstration areas. IDEMIA will showcase a wide range of innovations, such as: Identity on the move: secure biometric systems to manage the flow of people The mobile generation: a new solution to put your ID in your smartphone, in a safe way - under your control and wit

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme